tions were twice as likely in patients undergoing a repeated breast surgery (16.2%; 95% CI, 14.7%-17.7% vs 7.9%; 95% CI, 7.3%-8.5%; P < .001). Increased complications owing to a repeated surgery were statistically significant.
DNA mismatch repair status is a well-established biomarker in colorectal cancer and is associated with both a favorable prognosis and excellent response to immunotherapy.
1 However, the influence of deficient DNA mismatch repair (dMMR) and microsatellite instability in pancreatic ductal adenocarcinoma (PDAC) remains unknown. The prognosis of PDAC is typically dismal and treatment options are limited, but previous research has suggested that microsatellite instability in resected PDAC specimens may be associated with improved survival. Results | Among 821 patients included in the registry, 10 (1.2%) patients with PDAC were identified (Table) . Seven patients had pathogenic germline mutations in MLH1 (n = 4) and MSH2 (n = 3). The mean (SD) age of all patients was 57.2 (15.0) years, 7 patients were men, and 8 had a personal history of Lynch syndrome-associated cancers. Six patients presented with localized disease and underwent either pancreatoduodenectomy (n = 4) or distal pancreatectomy (n = 2) with curative intent. Among these 6 patients, adjuvant or neoadjuvant chemotherapy was delivered to 3 and chemoradiotherapy was provided to 2. The 5-year overall survival rate of these patients was 100% after a median follow-up of 93.1 months (95% CI, 52.5-201.7). Four patients who pre-sented with metastatic disease and were treated with systemic chemotherapy alone had a median overall survival of 16.5 months (95% CI, 7.2-24.0) and a 5-year overall survival rate of 25% ( Figure) .
Discussion | In this single-institution study of dMMR PDAC, we identified patients with defects in MLH1, MSH2, MSH6, and PMS2 genes due to both germline and sporadic causes. Although patients with dMMR were not immune to nodal and distant metastases, those with localized disease who underwent surgery with curative intent had remarkably good outcomes with a 5-year overall survival rate of 100%, which is significantly better than the 25% reported in the largest randomized clinical trial of surgical resection and adjuvant chemotherapy. 4 Patients who presented with metastatic disease also experienced better-than-expected outcomes, achieving a median of 16.5 months' survival with one 5-year survivor (95% CI, 7.2-24.0) compared with a median of 11.1 months in patients treated with FOLFIRINOX (fluorouracil, leucovorin calcium, irinotecan hydrochloride, and oxaliplatin) and 6.8 months in patients treated with gemcitabine hydrochloride. 5 These findings confirm those of previous studies, which suggested superior outcomes in patients with dMMR malignant neoplasms, presumably related to a more robust tumor-infiltrating immune response.
2
The limitation of this study is its retrospective, singleinstitution design and the inclusion of only patients referred to and evaluated in our familial and high-risk cancer clinic, 
